ORCA-3 was designed to evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily for a period of 6 weeks or 12 weeks compared to placebo. ORCA-3 randomized 792 adult smokers at 20 clinical trial sites in the United States.

2 days ago · ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms cytisinicline’s efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine ...

ORCA-3, a multisite, 3-group, double-blind, randomized placebo-controlled clinical trial, tested the efficacy and safety of cytisinicline for smoking cessation using the dosing regimen of 3 mg 3 times daily for 6 or 12 weeks. The trial was conducted at 20 sites in 15 US states. Adults (≥18 years old) were eligible if they currently smoked 10 ...

3 days ago · Similar to the first Phase 3 trial, ORCA-3 participants had an average age of 53 years, smoked a median of 20 cigarettes per day at baseline, and had a median smoking history of 36 years with four ...

3 days ago · About ORCA-3 The Phase 3 ORCA-3 trial evaluated 792 adults who smoked cigarettes daily and was conducted at 20 clinical trial locations in the U.S. The trial was initiated in January 2022 and ...

May 23, 2023 · ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo. Cytisinicline demonstrated 6x increase in odds of continuous smoking abstinence at 6 months.

3 days ago · Achieve Life Sciences (ACHV) announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association Internal Medicine. ORCA-3 was the second ...

Sep 27, 2022 · The ORCA-3 trial is Achieve Life Sciences’ second randomized Phase 3 trial evaluating the efficacy and safety of cytisinicline as a treatment for smoking cessation in adult smokers at 20 clinical trial locations in the United States.

ORCA-3 demonstrated statistically significant results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo. Cytisinicline demonstrated 6x increase in odds of continous smoking cessation at 6 months compared to placebo.